title: Beta-amyloid toxicity and reversal in embryonic rat septal neurons.
abstract: Alzheimer's disease is characterized mainly by loss of neurons from the septal nucleus. In this study, neurons from the septal nucleus of the embryonic day 16 (E16) rat were grown in culture with a plane of astrocytes from the embryonic rat and in a defined medium in the absence of serum. Neurons were treated with beta-amyloid (Abeta: 0.1, 1 and 10 microM) on day in vitro (DIV) 1 and DIV 4 and fluorescent microscopy was used to measure survival and apoptosis following exposure of the treated cells on DIV 7. Reversal of neurotoxicity was studied using the potentially neuroprotective agents nerve growth factor (NGF, 100 ng/ml), basic fibroblast growth factor (bFGF, 5 ng/ml), insulin-like growth factors (IGF1 and IGF2, 10 ng/ml) and estrogen (10 nM), administered on DIV 4 and DIV 5, that is, subsequent to the Abeta (10 microM)-induced neurotoxicity. Abeta caused a significant decrease in survival at 10 microM, and a significant increase in apoptosis at 0.1 and 10 microM. IGF1, IGF2 and bFGF all caused a reversal of the Abeta-induced neurotoxic effect on survival while NGF and estrogen did not under these experimental conditions.
authors: School of Natural and Health Sciences, SNHS-Biology 305, Barry University, 11300 NE 2nd Avenue, Miami Shores, FL 33161, USA.
authors: Karen
authors: K
authors: Jarvis
authors: Poincyane
authors: P
authors: Assis-Nascimento
authors: Laura M
authors: LM
authors: Mudd
authors: Jeremy R
authors: JR
authors: Montague
mesh_terms: D016229:Amyloid beta-Peptides / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000506:poisoning*; D000818:Animals; D017209:Apoptosis; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D004334:Drug Administration Schedule; D004622:Embryo, Mammalian / Q000166:cytology; D016222:Fibroblast Growth Factor 2; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology; D007335:Insulin-Like Growth Factor II / Q000494:pharmacology; D008856:Microscopy, Fluorescence; D009474:Neurons / Q000187:drug effects* / Q000502:physiology; D018696:Neuroprotective Agents / Q000494:pharmacology; D009498:Neurotoxins / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012688:Septum Pellucidum / Q000166:cytology / Q000196:embryology*
chemical_list: D016229:Amyloid beta-Peptides; D018696:Neuroprotective Agents; D009498:Neurotoxins; D016222:Fibroblast Growth Factor 2; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II
references: Glia. 2004 May;46(3):252-60
references: 15048848
references: Ann N Y Acad Sci. 2003 Dec;1010:604-9
references: 15033800
references: Growth Horm IGF Res. 2004 Jun;14 Suppl A:S39-43
references: 15135775
references: Eur J Cell Biol. 1984 Sep;35(1):55-61
references: 6489360
references: Neuroreport. 1993 Jun;4(6):760-2
references: 7688591
references: Brain Res. 1993 Sep 3;621(1):35-49
references: 8221072
references: J Neurotrauma. 1994 Feb;11(1):3-33
references: 8201625
references: Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4772-7
references: 9114067
references: Am J Med. 1997 Sep 22;103(3A):19S-25S
references: 9344403
references: J Neural Transm Suppl. 1998;54:259-67
references: 9850934
references: Brain Res Mol Brain Res. 2004 Nov 24;131(1-2):33-50
references: 15530650
references: J Endocrinol. 2004 Dec;183(3):605-15
references: 15590986
references: J Neurochem. 2005 Feb;92(3):607-15
references: 15659230
references: J Alzheimers Dis. 2004 Dec;6(6 Suppl):S13-7
references: 15665408
references: J Clin Endocrinol Metab. 2005 Mar;90(3):1775-82
references: 15585566
references: Exp Neurol. 2005 Aug;194(2):506-22
references: 15893308
references: NeuroRx. 2004 Jan;1(1):117-27
references: 15717012
references: NeuroRx. 2005 Jan;2(1):120-8
references: 15717063
references: J Mol Med (Berl). 2005 Sep;83(9):720-35
references: 16001231
references: Neurochem Res. 2005 Jun-Jul;30(6-7):895-908
references: 16187224
references: Cell Death Differ. 2006 Jul;13(7):1088-96
references: 16410806
references: Neuron. 2006 Jul 6;51(1):29-42
references: 16815330
references: J Neurosci. 2007 Jan 24;27(4):824-31
references: 17251422
references: Ann N Y Acad Sci. 2006 Nov;1089:324-42
references: 17261779
references: J Neurosci. 2007 Feb 7;27(6):1422-33
references: 17287517
references: Hum Reprod Update. 2007 Mar-Apr;13(2):175-87
references: 17135285
references: J Biol Chem. 2007 Apr 6;282(14):10203-9
references: 17301053
references: Neurochem Res. 2007 Sep;32(9):1476-82
references: 17406977
references: J Biomol Struct Dyn. 1999 Oct;17(2):381-91
references: 10563586
references: Brain Res Bull. 2000 Jan 1;51(1):35-42
references: 10654578
references: Ann N Y Acad Sci. 1999;890:356-64
references: 10668442
references: J Neurosci. 2002 Sep 1;22(17):7380-8
references: 12196559
references: Neurochem Res. 2002 Dec;27(12):1699-705
references: 12515325
references: Curr Drug Targets CNS Neurol Disord. 2003 Oct;2(5):315-34
references: 14529363
references: J Neurochem. 2003 Nov;87(3):733-41
references: 14535955
references: Annu Rev Med. 2004;55:15-25
references: 14746507
references: J Neural Transm (Vienna). 2004 Mar;111(3):387-411
references: 14991461
references: J Mol Med (Berl). 2004 Mar;82(3):156-62
references: 14647921
references: Eur J Pharmacol. 2004 Apr 19;490(1-3):127-33
references: 15094079